Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Azitra’s 200-page disclosures can feel like decoding a lab notebook. Clinical trial jargon, microbiome patents, and dilution clauses hide in footnotes just when you need clarity. That’s why investors searching for Azitra insider trading Form 4 transactions or the latest Azitra quarterly earnings report 10-Q filing come here first.
Stock Titan’s platform turns technical biotech prose into plain English. Our AI parses every submission the minute it hits EDGAR, delivering Azitra Form 4 insider transactions real-time alerts, one-click highlights of pipeline milestones, and side-by-side financial trend charts. Think of it as Azitra SEC filings explained simply—no more hunting for revenue runway or trial phase updates.
Whether you’re after a concise Azitra earnings report filing analysis, need help understanding Azitra SEC documents with AI, or want to spot patterns in Azitra executive stock transactions Form 4, everything is organized by form type:
- 10-K: Dive into an Azitra annual report 10-K simplified to uncover cash burn, licensing agreements, and microbiome IP strategy.
- 10-Q: Track quarter-over-quarter R&D spend and clinical updates.
- 8-K: Get Azitra 8-K material events explained within minutes of release—ideal for drug data announcements.
- DEF 14A: Review an Azitra proxy statement executive compensation breakdown to see how management aligns pay with trial progress.
From real-time filing alerts to AI-powered summaries, Stock Titan equips you to follow this precision-dermatology pioneer without wading through dense biotech terminology.
Azitra held its 2025 annual meeting on June 23, where stockholders voted on several key proposals. Three out of four proposals were concluded, while one remains pending:
- Board Elections: All four director nominees were successfully elected: Francisco D. Salva, Travis Whitfill, Barbara Ryan, and John Schroer, with each receiving over 1 million votes in favor
- Auditor Appointment: Stockholders ratified Grassi & Co., CPAs as the independent auditor for FY2025, with 8.37 million votes in favor
- Share Issuance: Approved issuance of >19.99% of outstanding common stock under purchase agreement with Alumni Capital LP, receiving 1.2 million favorable votes
- Pending Vote: Proposal to increase authorized common stock from 100M to 200M shares was adjourned to July 3, 2025, allowing additional time for stockholder voting
The company maintains its status as an emerging growth company and trades on NYSE American under symbol AZTR.
Azitra has filed a significant update regarding their 2025 Annual Meeting of Stockholders scheduled for June 23, 2025. The company has issued a supplement to their previously filed proxy statement, specifically addressing changes to the voting standard for Proposal 2.
The key proposal under consideration seeks stockholder approval to double the authorized common stock from 100,000,000 to 200,000,000 shares. This represents a material change to the company's capital structure that could significantly impact existing shareholders.
Key details:
- Annual Meeting to be held virtually on June 23, 2025, at 11:00 AM ET
- Original proxy statement filed May 29, 2025
- Supplementary proxy statement filed June 18, 2025
- Company maintains emerging growth company status
Stockholders are encouraged to review the complete proxy materials available on the SEC website before making voting decisions.
Azitra has filed a supplementary proxy statement (DEFA14A) to update voting requirements for their upcoming Annual Meeting on June 23, 2025. The key modification relates to Proposal 2, which seeks to increase authorized common stock from 100 million to 200 million shares.
Due to recent Delaware General Corporation Law amendments (Section 242(d)(2)), the voting standard has changed. The proposal now requires a majority of votes cast rather than a majority of outstanding shares. Key voting details:
- Abstentions will not count as votes "For" or "Against"
- Brokers have no discretionary voting authority
- Broker non-votes won't be counted as votes cast
Previously submitted proxies remain valid unless revoked. The Board unanimously recommends voting "FOR" all proposals. Shareholders can vote via Internet, telephone, or mail, and can change their votes through various methods including attending the virtual meeting on June 23, 2025.
FAQ
What is the current stock price of Azitra (AZTR)?
What is the market cap of Azitra (AZTR)?
What is the primary focus of Azitra Inc?
How does Azitra utilize the microbiome in its therapies?
Which skin conditions are targeted by Azitra's pipeline?
What technologies support Azitra's therapeutic development?
What differentiates Azitra Inc from other dermatology biotech companies?
How does the company ensure the safety of its product candidates?
What role does AI play in Azitra's operations?
How is Azitra Inc positioned within the dermatological market?
